ABSTRACT
INTRODUCTION
Methionine (MET) dependence, the elevated minimal MET requirement for cell growth relative to normal cells, has been observed in many human cancer cell lines and cancer xenografts in animal models (1) (2) (3) . MET dependence is a metabolic defect seen only in cancer cells and precludes the cells from growing in media in which methionine is depleted (4, 5) .
Recombinant methioninase (rMETase), chemical name: L-methionine ␣-deamino-␥-mercaptomethane lyase or EC 4.4.1.11, is a pyridoxal-L-phosphate (PLP)-dependent enzyme with four subunits of 43 KDa each. rMETase is found in Pseudomonas putida, Aeromonas, and Clostridium but not in yeast, plants, or mammals (1-7). The enzyme has been cloned from Pseudomonas putida and produced in Escherichia coli (8, 9) . rMETase has been demonstrated to be a powerful approach to methionine depletion in vivo (6, 7) .
rMETase alone or in combination with chemotherapeutic agents such as cisplatin, 5-fluorouracil, and 1,3-bis(2-chloroethyl)-1-nitrosourea has shown efficacy and synergy, respectively, in mouse models of colon, lung, and brain cancer (10 -13) . A pilot Phase I clinical trial demonstrated that rMETase depleted plasma methionine levels without observed clinical toxicity over a period of ϳ24 h in patients with advanced cancer (14, 15) . A recent study in primates, however, indicated that rMETase could cause anaphylactic reactions (16) .
Conjugation of protein therapeutics with polyethylene glycol (PEG) has been shown to confer important therapeutic benefits, most importantly reduced antigenicity (17) . The Food and Drug Administration has approved the PEGylated forms of several protein therapeutics for clinical use, including adenosine deaminase, asparaginase, ␣-IFN, and a growth hormone antagonist (18 -22) .
rMETase was coupled to methoxypolyethylene glycol succinimidyl glutarate-5000 (MEGC-PEG; Ref. 23) . Pharmacokinetic evaluation in mice showed that MEGC-PEG-rMETase had decreased antigenicity, increased serum half-life, and increased methionine depletion time compared with unmodified rMETase. However, the half-life of active MEGC-PEG-rMETase holoenzyme was shown to be limited because of in vivo dissociation of PLP (23) .
The present study demonstrates the dose dependence efficacy of infused PLP to markedly increase the serum half-life of the active holoenzyme form of PEGrMETase and the period of maintenance of serum MET depletion in mice, suggesting the clinical potential of the combination of MEGC-PEG-rMETase and PLP treatment.
MATERIALS AND METHODS
Materials. rMETase was produced by Shionogi Co., Ltd. (Osaka, Japan) as described previously (23) . The rMETase was formulated in 50 mM sodium phosphate buffer (pH 7.2), containing 10 M PLP, with protein concentration 31 mg/ml, and specific activity 50.7 units/mg. rMETase was Ͼ95% pure by high-performance liquid chromatography with a tetramer/oligomer ratio of 96.7/3.3 and endotoxin of 0.06 EU/mg. MEGC-PEG used for PEGylation of rMETase was provided by the NOF Corporation (Kawasaki-shi, Kanagawa, Japan). The average molecular mass was 5461 Da. PLP and other chemicals were purchased from Sigma (St. Louis, MO).
PEGylation. The protocol for preparation of PEGylated rMETase was previously described (23) : the activated MEGC-PEG derivative was used at a molar excess (2-fold) of MEGC-PEG to free lysines in rMETase (32 per rMETase tetramer), which corresponds to a molar ratio of PEG to rMETase of 60/1. A given amount of the activated MEGC-PEG was added to the rMETase solution (100 mg/ml) with three stepwise additions at 20-min intervals. The PEGylation reaction was carried out at 37°C (pH 9.0) under gentle stirring for 60 min. The PEGylation reaction was terminated by adjusting the pH to 7.2 with 0.1 M sodium diphosphate (pH 4.5). Diafiltration was followed by purification of MEGC-PEG-rMETase on DEAE-Sepharose and Sephacryl S200 columns. Purified MEGC-PEG-rMETase was concentrated and sterilized by filtration and stored at Ϫ80°C. PLP Infusion. Miniosmotic pumps with a reservoir volume of 200 l, pumping rate of 1.0 l/h and duration 7 days (Model 2001) were purchased from Durect Corporation (Cupertino, CA). Five-hundred mg of PLP and 150 mg of sodium hydroxide were dissolved in 1 ml of distilled water (pH 7.4). Other concentrations of PLP were prepared by dilution. The PLP solution was drawn into a 3-ml syringe, which was attached to the blunt-tipped, 27-gauge filling tube of the minipump. For s.c. placement of the pump, a small incision is made in the skin between the scapulae. Using a hemostat, a small pocket is formed by spreading the s.c. connective tissues apart. The pump is inserted into the pocket with the flow moderator pointing away from the incision. The skin incision is closed with sutures.
Determination of Protein Content. Protein was measured colorimetrically using the Wako Protein Assay kit (Wako, Osaka, Japan) according to the instruction manual with slight modification (24) .
Determination of PEGylation Degree of rMETase. The degree of modification of PEGylated rMETase was determined colorimetrically (25) and by matrix-assisted desorption ionization. For the colorimetric assay, various amounts of rMETase and MEGC-PEG-rMETase in 2 ml 0.1 M sodium phosphate buffer (pH 8.0) were mixed with 1 ml fluorescamine solution (0.3 mg/ml in acetone) and incubated for 5 min at room temperature. Samples were then assayed with a fluorescence spectrometer at 390 nm excitation and 475 nm emission. Results were plotted as fluorescence units versus concentration, with the slope of the line being determined by linear regression. The percentage of PEGylated primary amines was determined according to the following formula: 1 Ϫ (slope PEGylated rMETase/slope naked rMETase) ϫ 100. Matrixassisted desorption ionization analysis of naked and MEGC-PEG-rMETase was performed at the Scripps Research Institute using a PerSeptive Biosystems Voyager-Elite mass spectrometer (San Diego, CA).
Determination of MEGC-PEG-rMETase Apoenzyme. MEGC-PEGrMETase apoenzyme was determined, in the presence of PLP, from ␣-ketobutyrate produced from L-methionine according to the method of Esaki and Soda (26) with slight modification. Fifty l of sample, diluted in 100 mM potassium phosphate buffer (pH 8.0), containing 0.01% DTT, 1 mM EDTA 2 Na, 10 M PLP, and 0.05% Tween 80, were mixed with 1 ml substrate solution [100 mM potassium phosphate buffer (pH 8.0), containing 25 mM L-methionine and 10 M PLP] in a glass test tube. The reaction mixture was vortexed immediately and incubated at 37°C without shaking for precisely 10 min. The reaction was stopped by adding 100 l 50% trichloroacetic acid. The suspension was centrifuged at 13,000 rpm for 2 min. The supernatant (0.8 ml) was collected in a glass tube containing 1.6 ml of 1 M acetate buffer (pH 5.0). Then, 0.6 ml N-methyl-2-benzothiazolone hydrazone hydrochloride solution containing 0.1% 3-methyl-2-benzothiazolinone hydrazone hydrochloride monohydrate (Wako) was added to the tube, mixed well, and incubated at 50°C for 40 min. The absorbance of the reaction mixture was measured at 320 nm. The assay was carried out in triplicate. ⌬E was calculated by subtracting the average absorbance of blanks from the average absorbance of the reaction mixture. The enzyme activity was calculated by the following formula: activity (units/ml) ϭ 0.548 (1.07 ϩ 2.2⌬E) ⌬E. One unit of enzyme is defined as the amount of enzyme which produced 1 M ␣-ketobutyrate/minute at an infinite concentration of MET.
Determination of MEGC-PEG-rMETase Holoenzyme Activity. For determination of plasma MEGC-PEG-rMETase holoenzyme activity, no PLP was added in the substrate solution. All procedures were the same as for the determination of MEGBC-PEG-rMETase apoenzyme, except that 5 l of the sample in 45 l distilled water were mixed with 1 ml substrate solution in the first reaction step. Because of the change of sample volume, the enzyme activities are calculated from the following formula: activity (units/ml) ϭ 27.4 (1.07 ϩ 2.2⌬E) ⌬E.
Plasma MET Determination. The MET level in the plasma was measured by precolumn derivatization, followed by high-performance liquid chromatography separation (27) . Briefly, 10 l plasma sample or MET standard were precipitated with 30 l acetonitrile, followed by centrifugation at 10,000 rpm for 5 min. Ten l of the supernatant were mixed with 5 l of a fluoraldehyde derivative reagent, o-phthaldialdehyde, for 1 min at room temperature, followed by addition of 150 l 0.1 M sodium acetate (pH 7.0). Twenty l of the reaction mixture were loaded on a reversed-phase Supelcosil LC-18DB column (25 ϫ 4.8-cm, particle size 5 m; Supelco, Bellefonte, PA). The amino acid derivatives were separated by using a gradient elution of 40 -60% solution B (methanol) in solution A [tetrahydrofuran/methanol/0.1 M sodium acetate (pH 7.2); 5/95/900] at a flow rate of 1.5 ml/min. A fluorescence spectrophotometer was used for detection with excitation at 350 nm and emission at 450 nm. The plasma methionine was identified by the retention time of a MET standard solution and quantitated according to a MET standard curve.
Determination of Plasma PLP. PLP in plasma was determined based on the conversion of pyridoxal 5Ј-phosphate to 4-pyridoxic acid 5Ј-phosphate by cyanide in alkaline medium, followed by a high pressure liquid chromatographic separation (28) . All work was performed in a semi-darkened laboratory with low actinic lighting to avoid light-catalyzed destruction of the derivatives. Briefly, the diluted plasma sample and PLP standard solutions were mixed with an equal volume of trichloroacetic acid (100 g/liter) and incubated at 50°C in the dark for 5 min for removal of protein. After centrifugation at 10,000 rpm for 5 min, the supernates were taken and transferred to new vials. To 100 l of the resulting supernatant, 35.5 l dipotassium hydrogen phosphate (3.3 mM) were added, followed by 10 l sodium cyanide (0.04 mM). The reaction mixture was kept at 50°C for 25 min in the dark, then 12.5 l orthophosphoric acid (2.86 mM) were added. Fifty l of the supernatant were loaded on a Waters Symmetry Shield RP8, 5m, 4.6 ϫ 250 mm column (Blackmoor Lane, Watford, United Kingdom). The column was eluted with water containing 75 mM semicarbazide and 50 mM potassium dihydrogen phosphate (pH 2.85) at a flow rate of 1.5 ml/min. A fluorescence spectrophotometer was used for detection with excitation at 325 nm and emission at 418 nm. The PLP peak was identified by the retention time of a PLP standard. The concentration of plasma PLP was calculated using a calibration curve.
Treatment of Mice with MEGC-PEG-rMETase. BALB-C NCR nude mice ages 4 weeks (20 -25g) were used for the study with five mice/group. All animal studies were conducted in accordance with the principles and procedures outlined in the NIH National Research Council's "Guide for the Care and Use of Laboratory Animals" 5 under assurance number A3873-1. Osmotic pumps filled with 250 l PLP at different concentrations ranging from 5 to 500 mg/ml were implanted s.c. as described above. Twelve h after pump implantation, MEGC-PEG-rMETase at a dose of 4000 or 8000 units/kg was i.v. injected via the tail vein into each mouse, respectively. Blood (200 l) was collected from the retrorbital plexus of each animal using heparinized capillary tubes. Blood was collected before injection and 1, 8, 12, 24, 48, 72 , and 96 h after injection. The plasma was separated and stored in small aliquots at Ϫ80°C. MEGC-PEG-rMETase activity, methionine concentration and PLP level in the plasma were measured as described above.
RESULTS AND DISCUSSION
Characterization of MEGC-PEG-rMETase. rMETase was PEGylated at a ratio of MEGC-PEG to rMETase of 60:1, which resulted 5 Internet address: http://oacu.od.nih.gov/regs/guide/guidex.htm. in MEGC-PEG-rMETase molecules with a range of three to seven PEG chains/monomer of rMETase, specific enzyme activity, 44 units/mg (23) .
Dose Response of PLP Infusion on Plasma PLP Levels. The activity of rMETase depends on stable binding of PLP to the protein to form the holoenzyme (29) . We have previously shown that PLP readily dissociates from MEGC-PEG-rMETase in vivo (23) . To increase the time of maintenance of the holoenzyme form of PEGrMETase and MET-depletion time in vivo, PLP was continuously infused to MEGC-PEG-rMETase-treated mice using implanted miniosmotic pumps containing various concentrations of PLP. Plasma PLP levels were found to increase in a dose-dependent manner (Fig.  1) . Peak plasma PLP concentrations in mice implanted with 5, 50, 100, 200, and 500 mg/ml PLP-containing pumps resulted in 7, 24, 34, 60, and 95 M plasma concentrations, respectively, compared with a baseline of 0.3 M. Pumps with 200 mg/ml PLP could sustain plasma PLP at ϳ20 M for 24 h and 10 M for 72 h. Pumps with 500 mg/ml PLP could sustain plasma PLP levels at ϳ40 M for 48 h and 10 M for 96 h (Fig. 1) .
Dose Response of PLP Infusion on MEGC-PEG-rMETase Holoenzyme Half-Life. MEGC-PEG-rMETase holoenzyme activity is measured in vitro without addition of PLP in the enzyme assay solution. PEG-rMETase holoenzyme activity was markedly dependent on the dose of PLP infused in vivo (Table 1 , Fig. 2A ). MEGC-PEG-rMETase holoenzyme half-life was 1.5 h without PLP infusion, 2.5 h with 5 mg/ml PLP pumps, and ranged to 7 h with 500 mg/ml PLP pumps (Table 1) , a 4.5-fold increase compared with the PEG-rMETase half-life without PLP supplementation. A high degree of correlation of PLP concentration in Fig. 2 . Dose-dependent efficacy of PLP on plasma half-life of MEGC-PEG-rMETase holoenzyme (A) and apoenzyme (B) half-life. Osmotic pumps filled with PLP ranging from 5 to 500 mg/ml were implanted s.c. MEGC-PEG-rMETase at a dose of 4000 units/kg was i.v. injected into each mouse 12 h after pump implantation. Blood samples were collected at different time points and measured for PEG-rMETase holoenzyme (A) and apoenzyme (B) activity as described in "Materials and Methods." Fig. 3 . Time and extent of plasma MET depletion by MEGC-PEG-rMETase at various doses of PLP infusion. Osmotic pumps filled with PLP ranging from 5 to 500 mg/ml were implanted s.c. PEG-rMETase at a dose of 4000 units/kg (A) or 8000 units/kg (B) was i.v. injected into each mouse 12 h after pump implantation. Blood samples were collected at different time points and measured for plasma MET level as described in "Materials and Methods." NOTE. Osmotic pumps containing PLP ranging from 5 to 500 mg/ml were implanted s.c. MEGC-PEG-rMETase at 4000 units/kg was i.v. injected in each mouse 12 h after pump implantation. Blood samples were collected at different time points and measured for MEGC-PEG-rMETase apoenzyme and holoenzyme enzyme activity as described in "Materials and Methods." Fig. 2A ). In contrast, the half-life of PEG-rMETase apoenzyme, measured in the presence of PLP in vitro, was ϳ18 h in animals with or without PLP infusion (Table 1 , Fig. 2B ). Thus, MEGC-PEG-rMETase holoenzyme half-life was highly dependent on the dose of PLP in contrast to apoenzyme half-life ( Fig. 2A) .
Dose Response of PLP Infusion on Time of MET Depletion by PEG-rMETase. MEGC-PEG-rMETase holoenzyme half-life highly correlated with time of MET depletion, both of which depend on the dose of infused PLP (Table 2, Fig. 3, A and B) . PLP-supplemented mice were injected with a single i.v. injection of 4000 or 8000 units/kg PEGrMETase. Blood samples were collected at various time points and measured for plasma MET concentration. Four-thousand units/kg MEGC-PEG-rMETase administration in the mice infused with 5, 50, 200, and 500 mg/ml PLP-containing pumps resulted in plasma MET depletion to Յ5 M for 8, 24, 72, and 72 h, respectively (Table 2, Fig.  3A) , demonstrating a strong PLP dose dependence of MET depletion. The mice receiving 8000 units/kg PEG-rMETase and the same varying amounts of PLP showed a similar plasma MET depletion time course (Table 2 , Fig. 3B ). However, mice given 8000 units/kg MEGC-PEGrMETase supplemented with 500 mg/ml PLP had no detectable levels of MET for 72 h (Fig. 3B) . The efficacy of PLP to extend the time of MEGC-PEG-rMETase-mediated MET depletion to Յ 5 M was linearly dose dependent on PLP up to 200 mg/ml in the osmotic pump (r 2 ϭ 0.99; Fig. 4 ). Five-hundred mg/ml PLP-containing pumps did not further extend the time of MET depletion.
This study indicated that PLP supplementation in vivo greatly extended the half-life of MEGC-PEG-rMETase holoenzyme, which in turn greatly extended the time of MET depletion by MEGC-PEGrMETase in a dose-dependent manner. PLP extended the half-life of MEGC-PEG-rMETase holoenzyme ϳ4 -5-fold in a dose-dependent manner, which resulted in a ϳ10-fold increase in time of plasma MET depletion to Յ5 m. PLP appeared to either associate with the MEGC-PEG-rMETase apoenzyme or prevent PLP dissociation from the holoenzyme in the plasma. Although PLP remains tightly bound to the enzyme in vitro, it readily dissociates from the enzyme in vivo. In a recent study with macaque monkeys, MEGC-PEG-rMETase had an extended apoenzyme half-life of 90-143 h, 6 but holoenzyme half-life was only 1.5 h. The results of the present study in mice suggest that PLP would greatly extend holoenzyme half-life in primates as well as humans. The combination of MEGC-PEG-rMETase treatment with PLP supplementation suggests an effective clinical strategy for longterm MET depletion to arrest cancer cell growth.
